NCT04220970 Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry
| NCT ID | NCT04220970 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Lymphoma Academic Research Organisation |
| Condition | Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2017-06-07 |
| Primary Completion | 2032-06-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2017-06-07 with a primary completion date of 2032-06-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) is a rare disease seen only in women with a breast implant. Because of the low incidence of this disease and the peculiar histological subtype, French authorities, in accordance with the recommendations of an expert group, recommended the implementation of a BIA-ALCL case registry, in connection with a national Multidisciplinary meeting (Réunion de Concertation Pluridisciplinaire nationale de recours- RCP). This registry is opened in France and in Belgium
Eligibility Criteria
Inclusion Criteria: * Adult patients with an anaplastic large cell lymphoma associated with breast implants Exclusion Criteria: \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04220970 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04220970 currently recruiting?
Yes, NCT04220970 is actively recruiting participants. Contact the research team at manon.croix.ext@lysarc.org for enrollment information.
Where is the NCT04220970 trial being conducted?
This trial is being conducted at Bruges, Belgium, Brussels, Belgium, Brussels, Belgium, Brussels, Belgium and 11 additional locations.
Who is sponsoring the NCT04220970 clinical trial?
NCT04220970 is sponsored by The Lymphoma Academic Research Organisation. The trial plans to enroll 150 participants.